1. Cimetidine: An anticancer drug?
   Martina Kubecova et al, 2011, European Journal of Pharmaceutical Sciences CrossRef
2. Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets
   Phuong Linh Nguyen et al, 2021, Biomolecules CrossRef
3. Lectins as possible tools for improved urinary bladder cancer management
   Tanja Višnjar et al, 2019, Glycobiology CrossRef
4. Cimetidine Attenuates Therapeutic Effect of Anti-PD-1 and Anti-PD-L1 and Modulates Tumor Microenvironment in Colon Cancer
   Feng-Chi Kuo et al, 2024, Biomedicines CrossRef
5. Inhibition of E-selectin expression on the surface of endothelial cells inhibits hepatocellular carcinoma growth by preventing tumor angiogenesis
   Patrick Borentain et al, 2016, Cancer Chemotherapy and Pharmacology CrossRef
6. Blood-based protein biomarkers in bladder urothelial tumors
   Rubén López-Cortés et al, 2021, Journal of Proteomics CrossRef
7. Pharmacological interventions part IV: Metabolic modifiers
   Tomas Koltai et al, 2020, An Innovative Approach to Understanding and Treating Cancer: Targeting pH CrossRef
8. H2 antihistamines: May be useful for combination therapies in cancer?
   Nora A. Mohamad et al, 2024, Biochemical Pharmacology CrossRef
9. Animal models of urinary bladder cancer and their application to novel drug discovery
   Paula A Oliveira et al, 2014, Expert Opinion on Drug Discovery CrossRef
10. NTPDase3 and ecto-5′-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression
    Liliana Rockenbach et al, 2014, Purinergic Signalling CrossRef
11. Resistance to antiangiogenic treatments: A review
    Tomas Koltai et al, 2022, Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy CrossRef